Drug class
Atypical antipsychotic; selective dopamine D2/D3 receptor antagonist
Mechanism of action
Selectively antagonises dopamine D2 and D3 receptors in limbic and other dopaminergic pathways. At therapeutic doses it reduces dopaminergic neurotransmission associated with psychotic symptoms; effects depend on dose and receptor occupancy.
General use cases
- Treatment of schizophrenia, including positive and negative symptoms, under product-specific authorisation; oral and intravenous formulations may have different indications in different jurisdictions
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
